Rare diseases
Investigational molecules
Locations
Sandakerveien 138, 0484 Oslo, Norway
Lytix Biopharma AS is focused on clinical research in advanced melanoma, with particular attention to patients whose disease has progressed after PD-1 and PD-L1 inhibitor therapy. The sponsor’s clinical activity is centered on treatment-resistant cancer populations in need of new therapeutic options.
The research interest is concentrated on oncology settings where immune-based treatment resistance limits current care.
Lytix Biopharma AS runs clinical trials in conditions such as Malignant melanoma, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
